Skip to main content
. 2019 Nov 26;2019(11):CD009286. doi: 10.1002/14651858.CD009286.pub3

Burns 1999.

Methods Parallel design
Analysis: ITT: 2 withdrawn and 1 death (treatment), 1 death (placebo), last value carried forward
Participants Diagnosis: stroke.
Months from stroke: median (range) 10.5 months (1 ± 156) in sertraline group and 5.5 months (1.5 ± 48) in the control group
Treatment: 14 people
Control: 14 people
Exclusion criteria: less than 1 month since stroke, depression or dementia using the DSM III‐R criteria
Interventions Treatment: sertraline 50 mg daily
Control: matched placebo
Duration: treatment continued for 8 weeks
Duration of follow‐up: 2 weeks off treatment. All scores became non‐significant (though data not reported so could not be used in the analysis)
Outcomes Able to use:
  • improved score on lability scale

  • improved score on clinician's interview based impression of change

  • diminished tearfulness

  • leaving the study early

  • death

  • AEs


Method of collecting AEs was not stated
Unable to use: MADRS, BI, MMSE (data not presented)
Funding source Funded by an unrestricted personal grant from Pfizer, the manufacturers of sertraline
Notes Dates of study not stated, conflicts of interest not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Blocks of 4 using list produced by medical statistics department
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel (performance bias) 
 All outcomes Low risk Matched placebo
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk Run‐out was single‐blind, treatment was double‐blind, but unclear whether outcome assessors were blind
Incomplete outcome data (attrition bias) 
 All outcomes Low risk Analysis: ITT, LOCF
Selective reporting (reporting bias) Low risk Trial details published on www.strokecentre.org/trials, although unable to use data from MADRS
Given that the main aim was to explore effect on emotionalism, this is unlikely to have biased results
Other bias Unclear risk Placebo group younger, uncertain influence on bias
Statistical analysis was carried out independently by the Applied Statistics Research Unit in Canterbury